Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Dec 15, 2024; 16(12): 4650-4662
Published online Dec 15, 2024. doi: 10.4251/wjgo.v16.i12.4650
Table 1 Baseline characteristics of low and high γ-glutamyl transferase to albumin ratio groups before propensity score matching
Variables
Total
GAR-low
GAR-high
P value
Patients1231706525
Gender< 0.001
Female, n (%)187 (0.15)129 (0.18)58 (0.11)
Male, n (%)1044 (0.85)577 (0.82)467 (0.89)
Age ≥ 60 years, n (%)501 (0.41)305 (0.43)196 (0.37)0.044
HBV, n (%)749 (0.61)432 (0.61)317 (0.60)0.819
HCV, n (%)38 (0.03)27 (0.04)11 (0.02)0.117
Alcohol, n (%)482 (0.39)243 (0.34)239 (0.46)< 0.001
Diabetes, n (%)122 (0.10)69 (0.10)53 (0.10)0.928
Hypertension, n (%)178 (0.14)106 (0.15)72 (0.14)0.576
ALT levels ≥ 40, U/L, n (%)639 (0.52)274 (0.39)365 (0.70)< 0.001
ALP levels ≥ 125, U/L, n (%)714 (0.58)249 (0.35)465 (0.89)< 0.001
Serum AFP ≥ 500, ng/mL, n (%)528 (0.43)254 (0.36)274 (0.52)< 0.001
Child-Pugh class, n (%)< 0.001
    A920 (0.75)585 (0.83)335 (0.64)
    B297 (0.24)114 (0.16)183 (0.35)
    C14 (0.01)7 (0.01)7 (0.01)
Lymph node metastasis, n (%)617 (0.50)312 (0.44)305 (0.58)< 0.001
Extrahepatic metastasis, n (%)238 (0.19)116 (0.16)122 (0.23)0.004
PVTT, n (%)484 (0.39)196 (0.28)288 (0.55)< 0.001
BCLC stage, n (%)< 0.001
    A177 (0.14)137 (0.19)40 (0.08)
    B188 (0.15)129 (0.18)59 (0.11)
    C853 (0.69)433 (0.61)420 (0.80)
    D13 (0.01)7 (0.01)6 (0.01)
Number of tumors ≥ 2, n (%)890 (0.72)469 (0.66)421 (0.80)< 0.001
Tumor diameter, cm, n (%)< 0.001
    < 3172 (0.14)133 (0.19)39 (0.07)
    ≥ 3, < 5216 (0.18)155 (0.22)61 (0.12)
    ≥ 5, < 10491 (0.40)302 (0.43)189 (0.36)
    ≥ 10352 (0.29)116 (0.16)236 (0.45)
GAR-low: γ-glutamyl transferase to albumin ratio < 4.75; GAR-high: γ-glutamyl transferase to albumin ratio ≥ 4.75; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AFP: Alpha-fetoprotein; PVTT: Portal vein tumor thrombus; BCLC: Barcelona Clinic Liver Cancer.